RenalytixAI Announces Pricing of Global Offering and Approval to List on the Nasdaq Global Market
NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved …